Estramustine binding protein in primary tumours and metastases of malignant melanoma.
The presence of estramustine binding protein (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the estrogen receptor, was investigated in a pilot study of primary malignant melanomas and their metastases. In 11 primary melanomas EMBP was demonstrated by immunohistochemistry. The percentage of positive melanoma cells ranged between 11-91% with a mean of 57%. Radioimmunoassay on metastatic tissue revealed significant amounts of EMBP, with values ranging between 0.6-4.2 with a mean of 1.6 ng/mg protein. A high number of cells with a positive stain for EMBP in the primary tumours was significantly correlated to a short interval between diagnosis and the occurrence of metastases. Presence of EMBP in malignant melanoma may have prognostic significance and the role of hormone-linked cytostatic drugs in the treatment of this disease needs further investigation.
von Schoultz
E
E
Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
Carlström
K
K
Henriksson
R
R
Lagerlöf
B
B
Hansson
J
J
D000328:Adult; D000368:Aged; D002352:Carrier Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000737:chemistry; D008297:Male; D008545:Melanoma / Q000737:chemistry* / Q000556:secondary*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D029584:Prostatic Secretory Proteins; D011863:Radioimmunoassay; D012878:Skin Neoplasms / Q000737:chemistry* / Q000556:secondary*
D002352:Carrier Proteins; D009363:Neoplasm Proteins; D029584:Prostatic Secretory Proteins; C028321:estramustine-binding protein